A group of inherited metabolic diseases characterized by the accumulation of excessive amounts of acid mucopolysaccharides, sphingolipids, and/or glycolipids in visceral and mesenchymal cells. Abnormal amounts of sphingolipids or glycolipids are present in neural tissue. INTELLECTUAL DISABILITY and skeletal changes, most notably dysostosis multiplex, occur frequently. (From Joynt, Clinical Neurology, 1992, Ch56, pp36-7)

Mucolipidosis type IV: the origin of the disease in the Ashkenazi Jewish population. (1/185)

Mucolipidosis type IV (MLIV) is a neurodegenerative lysosomal storage disease in which most of the patients diagnosed hitherto are Ashkenazi Jews. The basic metabolic defect causing this disease is still unknown and the relevant gene has not yet been mapped or cloned. Seventeen Israel Ashkenazi families with MLIV patients had been interviewed to study their family origin. Although the families immigrated to Israel from various European countries they all could trace their roots three to four generations back to northern Poland or the immediate neighbouring country, Lithuania. Furthermore, there are only one or two ultraorthodox families among the 70-80 Ashkenazi families with MLIV patients worldwide, a marked under-representation of this group which constitutes at least 10% of the Ashkenazi population. This data indicate that MLIV mutation occurred only around the 18th and 19th centuries, after the major expansion of this population, in a founder in this defined European region belonging to a more modern, secular family.  (+info)

Mucolipidosis IV consists of one complementation group. (2/185)

Mucolipidosis IV (MLIV) is an autosomal recessive disorder of unknown etiology characterized by severe visual impairment and psychomotor retardation. Recently, there has been considerable interest in positional cloning of the MLIV gene. It is unknown whether MLIV is a genetically homogenous disorder. In this paper, we present experiments that determined whether the MLIV phenotype in fibroblasts could be corrected by fusing normal cells to MLIV cells and fusing fibroblasts from pairs of patients. All of our MLIV patients fulfilled several diagnostic criteria that we developed. In addition, we found high sensitivity to chloroquine in cultured fibroblasts from MLIV patients. We found that normal cells corrected the MLIV phenotype. Fusion products of normal and MLIV fibroblasts, but not MLIV fibroblasts themselves, were relatively protected against chloroquine selection. In addition, 74% of the normal-to-patient fusion products had reduced levels or total loss of MLIV characteristic autofluorescence. However, there was no complementation of the phenotype in fibroblast cultures from any of our MLIV patients, including those of non-Jewish ancestry. In fusion products of MLIV cultures from 24 patients, 90-100% of the cells remained autofluorescent. These results indicate that all of our known MLIV patients, regardless of ancestry or severity of the developmental defect, have a single mutated gene.  (+info)

Mapping of the mucolipidosis type IV gene to chromosome 19p and definition of founder haplotypes. (3/185)

Mucolipidosis type IV (MLIV) is a lysosomal storage disorder characterized by severe neurologic and ophthalmologic abnormalities. It is a rare autosomal recessive disease, and the majority of patients diagnosed, to date, are of Ashkenazi Jewish descent. We have mapped the MLIV gene to chromosome 19p13.2-13.3 by linkage analysis with 15 markers in 13 families. A maximum LOD score of 5.51 with no recombinants was observed with marker D19S873. Several markers in the linked interval also displayed significant linkage disequilibrium with the disorder. We constructed haplotypes in 26 Ashkenazi Jewish families and demonstrate the existence of two founder chromosomes in this population. The localization of MLIV to chromosome 19 will permit genetic prenatal diagnosis in affected families and will aid in the isolation of the disease gene.  (+info)

Orthopaedic management in four cases of mucolipidosis type III. (4/185)

Four patients with mucolipidosis type III, three of them brothers, were seen initially in the first two decades of life. Their main symptoms were carpal tunnel syndrome, trigger fingers and generalized joint stiffness. Radiographs showed spinal deformities and hip dysplasia, but these were not causing pain. Carpal tunnel syndrome was treated surgically but joint stiffness and hip and knee contractures were managed by physiotherapy. Up to the age of 24 none of these patients has had pelvic osteotomy for hip dysplasia; this operation, not yet reported in mucolipidosis type III, may eventually be necessary.  (+info)

Molecular basis of GM1 gangliosidosis and Morquio disease, type B. Structure-function studies of lysosomal beta-galactosidase and the non-lysosomal beta-galactosidase-like protein. (5/185)

GM1 gangliosidosis and Morquio B disease are distinct disorders both clinically and biochemically yet they arise from the same beta-galactosidase enzyme deficiency. On the other hand, galactosialidosis and sialidosis share common clinical and biochemical features, yet they arise from two separate enzyme deficiencies, namely, protective protein/cathepsin A and neuraminidase, respectively. However distinct, in practice these disorders overlap both clinically and biochemically so that easy discrimination between them is sometimes difficult. The principle reason for this may be found in the fact that these three enzymes form a unique complex in lysosomes that is required for their stability and posttranslational processing. In this review, I focus mainly on the primary and secondary beta-galactosidase deficiency states and offer some hypotheses to account for differences between GM1 gangliosidosis and Morquio B disease.  (+info)

Molecular basis of variant pseudo-hurler polydystrophy (mucolipidosis IIIC) (6/185)

Mucolipidosis IIIC, or variant pseudo-Hurler polydystrophy, is an autosomal recessive disease of lysosomal hydrolase trafficking. Unlike the related diseases, mucolipidosis II and IIIA, the enzyme affected in mucolipidosis IIIC (N-Acetylglucosamine-1-phosphotransferase [GlcNAc-phosphotransferase]) retains full transferase activity on synthetic substrates but lacks activity on lysosomal hydrolases. Bovine GlcNAc-phosphotransferase has recently been isolated as a multisubunit enzyme with the subunit structure alpha(2)beta(2)gamma(2). We cloned the cDNA for the human gamma-subunit and localized its gene to chromosome 16p. We also showed, in a large multiplex Druze family that exhibits this disorder, that MLIIIC also maps to this chromosomal region. Sequence analysis of the gamma-subunit cDNA in patients from 3 families identified a frameshift mutation, in codon 167 of the gamma subunit, that segregated with the disease, indicating MLIIIC results from mutations in the phosphotransferase gamma-subunit gene. This is to our knowledge the first description of the molecular basis for a human mucolipidosis and suggests that the gamma subunit functions in lysosomal hydrolase recognition.  (+info)

Characterization of the sialidase molecular defects in sialidosis patients suggests the structural organization of the lysosomal multienzyme complex. (7/185)

Sialidosis is an autosomal recessive disease caused by the genetic deficiency of lysosomal sialidase, which catalyzes the hydrolysis of sialoglycoconjugates. The disease is associated with progressive impaired vision, macular cherry-red spots and myoclonus (sialidosis type I) or with skeletal dysplasia, Hurler-like phenotype, dysostosis multiplex, mental retardation and hepatosplenomegaly (sialidosis type II). We have analyzed the genomic DNA from nine sialidosis patients of multiple ethnic origin in order to find mutations responsible for the enzyme deficiency. The activity of the identified variants was studied by transgenic expression. One patient had a frameshift mutation (G623delG deletion), which introduced a stop codon, truncating 113 amino acids. All others had missense mutations: G679G-->A (Gly227Arg), C893C-->T (Ala298Val), G203G-->T (Gly68Val), A544A-->G (Ser182Gly) C808C-->T (Leu270Phe) and G982G-->A (Gly328Ser). We have modeled the three-dimensional structure of sialidase based on the atomic coordinates of the homologous bacterial sialidases, located the positions of mutations and estimated their potential effect. This analysis showed that five mutations are clustered in one region on the surface of the sialidase molecule. These mutations dramatically reduce the enzyme activity and cause a rapid intralysosomal degradation of the expressed protein. We hypothesize that this region may be involved in the interface of sialidase binding with lysosomal cathepsin A and/or beta-galactosidase in their high-molecular-weight complex required for the expression of sialidase activity in the lysosome.  (+info)

Cloning of the gene encoding a novel integral membrane protein, mucolipidin-and identification of the two major founder mutations causing mucolipidosis type IV. (8/185)

Mucolipidosis type IV (MLIV) is an autosomal recessive lysosomal storage disorder characterized by severe psychomotor retardation and ophthalmologic abnormalities, including corneal opacity, retinal degeneration, and strabismus. Unlike the situation in other lysosomal disorders, the accumulation of heterogeneous storage material observed in MLIV does not result from a block in the catabolic pathways but is due to an ill-defined transport defect in the late steps of endocytosis. With the aim of cloning the MLIV gene, we searched in the 19p13.2-13.3 region, where the locus previously had been assigned by linkage mapping. In this region, we have identified a novel gene that is mutated in all patients with MLIV who were enrolled in our study. One patient was homozygous for the splice-acceptor mutation, and another was homozygous for a deletion removing the first six exons of the gene. In addition, four compound heterozygotes for these two mutations were identified. Haplotype analysis indicates that we have identified the two major founder mutations, which account for >95% of MLIV chromosomes in Ashkenazi Jewish patients. The gene, ML4, encodes a protein named "mucolipidin, " which localizes on the plasma membrane and, in the carboxy-terminal region, shows homologies to polycystin-2, the product of the polycystic kidney disease 2 gene (PKD2) and to the family of transient receptor potential Ca(2+) channels. Mucolipidin is likely to play an important role in endocytosis.  (+info)

Mucolipidoses are a group of inherited metabolic disorders characterized by the accumulation of complex carbohydrates (muco-) and fatty substances (lipids) in various tissues and cells (-oses). This is due to deficiency in enzymes that help break down these substances within lysosomes, which are organelles responsible for recycling and breaking down waste materials inside the cell.

There are four main types of mucolipidoses (I, II, III, and IV), each resulting from specific genetic mutations affecting different enzymes or proteins involved in the lysosomal degradation pathway. The symptoms, severity, and age of onset can vary widely among these types, ranging from mild to severe and including developmental delays, bone abnormalities, vision and hearing loss, heart problems, and coarse facial features.

Mucolipidoses are typically inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of the mutated gene (one from each parent) to develop the condition. However, mucolipidosis II is caused by X-linked inheritance, where a single copy of the mutated gene on the X chromosome is enough to cause the disorder.

Early diagnosis and management of mucolipidoses can help improve quality of life and slow disease progression. Treatment options include physical therapy, occupational therapy, speech therapy, medications for symptom management, and in some cases, enzyme replacement therapy or bone marrow transplantation.

Medical genetics of Ashkenazi Jews mucolipidoses at NINDS RESERVED, INSERM US14 -- ALL RIGHTS. "Orphanet: Mucolipidosis type II ... The mucolipidoses are inherited in an autosomal recessive manner, that is, they occur only when a child inherits two copies of ... Mucolipidosis is a group of inherited metabolic disorders that affect the body's ability to carry out the normal turnover of ... Mucolipidosis types II and III (ML II and ML III) result from a deficiency of the enzyme N-acetylglucosamine-1- ...
See the equivalent section in the main mucolipidosis article. Mucolipidosis type IV is severely under-diagnosed. It is often ... Mucolipidosis type IV (ML IV, ganglioside sialidase deficiency, or ML4) is an autosomal recessive lysosomal storage disorder. ... Mucolipidosis type 4 at NIH's Office of Rare Diseases (Articles needing additional references from April 2020, All articles ... Chen, C. S.; Bach, G; Pagano, R. E. (1998). "Abnormal transport along the lysosomal pathway in Mucolipidosis, type IV disease ...
They are seen in Mucolipidosis II, and Mucolipidosis III, also called inclusion-cell or I-cell disease where lysosomal enzyme ... ISBN 978-1-4160-6257-8. "Mucolipidoses Fact Sheet , National Institute of Neurological Disorders and Stroke". www.ninds.nih.gov ...
"Diseases: Mucolipidosis". Mount Sinai - Center for Jewish Genetic Diseases - Department of Human Genetics. Archived from the ... Compared to other ethnic groups, they more frequently act as carriers of mucolipidosis and Niemann-Pick disease, the latter of ... "Ashkenazi Disorders: Mendelian - Mucolipidosis IV". The Chicago Center for Jewish Genetic Disorders. "Myeloproliferative ... Kaposi's sarcoma Maple syrup urine disease Mucolipidosis IV Myeloproliferative neoplasms including polycythemia vera and ...
NLRP3 Mucolipidosis II alpha/beta; 252500; GNPTAB Mucolipidosis III alpha/beta; 252600; GNPTAB Mucolipidosis III gamma; 252605 ... GNPTAG Mucolipidosis IV; 252650; MCOLN1 Mucopolysaccharidosis Ih; 607014; IDUA Mucopolysaccharidosis Ih/s; 607015; IDUA ...
Mucolipidosis type I (ML I) is an inherited lysosomal storage disease that results from a deficiency of the enzyme alpha-N - ... mucolipidoses at NINDS - article derived from detail sheet available here Sialidosis type 1 and 3 at NIH's Office of Rare ... Fucosidosis Mucolipidosis James, William D.; Berger, Timothy G.; et al. (2006). Andrews' Diseases of the Skin: clinical ...
Plasma gastrin concentration is elevated in virtually all individuals with mucolipidosis type IV (mean 1507 pg/mL; range 400- ... "Constitutive achlorhydria in mucolipidosis type IV". Proceedings of the National Academy of Sciences of the United States of ...
"Mucolipidosis type II (Concept Id: C2673377)". www.ncbi.nlm.nih.gov. Retrieved 2023-07-03. "Muenke syndrome (Concept Id: ...
Amir, Naomi; Zlotogora, Joel; Bach, Gideon (June 1987). "Mucolipidosis Type IV: Clinical Spectrum and Natural History". ...
A symptom of rare diseases such as mucolipidosis (type IV). A symptom of Helicobacter pylori infection which neutralizes and ...
Dong X, Cheng X, Mills E, Delling M, Wang F, Kurz T, Xu H (2008). "The Type IV Mucolipidosis-Associated Protein TRPML1 is an ... GeneReviews/NIH/NCBI/UW entry on Mucolipidosis IV mucolipin-1+protein,+human at the U.S. National Library of Medicine Medical ... TRPML1 is a 65 kDa protein associated with mucolipidosis type IV. Its predicted structure includes six transmembrane domains, a ... mucolipidosis type IV TRPML GRCh38: Ensembl release 89: ENSG00000090674 - Ensembl, May 2017 GRCm38: Ensembl release 89: ...
Persons with mucolipidosis may share some of the clinical features associated with the mucopolysaccharidoses (certain facial ... Another lysosomal storage disease often confused with the mucopolysaccharidoses is mucolipidosis. In this disorder, excessive ...
Saul RA, Proud V, Taylor HA, Leroy JG, Spranger J (2005). "Prenatal mucolipidosis type II (I-cell disease) can present as ... "Distinguishing Pacman dysplasia from mucolipidosis II: comment on Saul et al. [2005]". Am J Med Genet A. 135 (3): 333. doi: ...
Mucolipidosis type 3 A at NIH's Office of Rare Diseases mucolipidoses at NINDS - original text of article derived from detail ... August 2006). "When Mucolipidosis III meets Mucolipidosis II: GNPTA gene mutations in 24 patients". Mol. Genet. Metab. 88 (4): ... As in Mucolipidosis II (I-cell disease), Mucolipidosis III results from genetic defects in GlcNAc phosphotransferase (N- ... Mucolipidosis "Mucolipidosis III alpha/beta , Genetic and Rare Diseases Information Center (GARD) - an NCATS Program". ...
Venkatachalam K, Hofmann T, Montell C (2006). "Lysosomal localization of TRPML3 depends on TRPML2 and the mucolipidosis- ...
... gets its name from the neurodevelopmental disorder mucolipidosis IV. Mucolipidosis IV was first discovered in 1974 by E.R. ... a new variant of mucolipidosis". The Journal of Pediatrics. 84 (4): 519-26. doi:10.1016/s0022-3476(74)80671-2. PMID 4365943. ...
"mucolipidosis II" at Dorland's Medical Dictionary Plante M, Claveau S, Lepage P, et al. (March 2008). "Mucolipidosis II: a ... mucolipidoses at NINDS - article derived from detail sheet available here I cell disease at NIH's Office of Rare Diseases ... Mucolipidosis II (ML II) is a particularly severe form of ML that has a significant resemblance to another ... 2005). "Mucolipidosis II is caused by mutations in GNPTA encoding the alpha/beta GlcNAc-1-phosphotransferase". Nat. Med. 11 (10 ...
... type C and Mucolipidosis IV. When NAADP mobilizes Ca2+ from these stores, the pH of the stores concomitantly increases (becomes ...
... and mucolipidosis. Metabolic Storage Diseases:, Tay-Sachs disease Farber disease GM1 and GM2 gangliosidoses Metachromatic ...
Mucolipidosis type IV is caused by mutations in the gene encoding the TRPML1 channel Mutations in and overexpression of ion ...
... mucolipidoses MeSH C05.116.198.495 - osteomalacia MeSH C05.116.198.579 - osteoporosis MeSH C05.116.198.579.610 - osteoporosis, ...
... mucolipidoses MeSH C10.228.140.163.100.435.810 - sialic acid storage disease MeSH C10.228.140.163.100.435.825 - ...
Mucolipidoses Also, glycogen storage disease type II (Pompe disease) is a defect in lysosomal metabolism as well, although it ... Mucolipidosis Type I (sialidosis) Type II (I-cell disease) Type III (pseudo-Hurler polydystrophy / phosphotransferase ...
... mucolipidoses MeSH C18.452.100.100.435.810 - sialic acid storage disease MeSH C18.452.100.100.435.825 - sphingolipidoses MeSH ... mucolipidoses MeSH C18.452.648.151.435.810 - sialic acid storage disease MeSH C18.452.648.151.435.825 - sphingolipidoses MeSH ... mucolipidoses MeSH C18.452.648.595.554.810 - sialic acid storage disease MeSH C18.452.648.595.554.825 - sphingolipidoses MeSH ... mucolipidoses MeSH C18.452.648.202.715 - mucopolysaccharidoses MeSH C18.452.648.202.715.640 - mucopolysaccharidosis I MeSH ...
... mucolipidoses MeSH C16.320.565.150.435.810 - sialic acid storage disease MeSH C16.320.565.150.435.825 - sphingolipidoses MeSH ... mucolipidoses MeSH C16.320.565.580.554.810 - sialic acid storage disease MeSH C16.320.565.580.554.825 - sphingolipidoses MeSH ... mucolipidoses MeSH C16.320.565.202.715 - mucopolysaccharidoses MeSH C16.320.565.202.715.640 - mucopolysaccharidosis I MeSH ...
... mucolipidosis, Frank-ter Haar syndrome, crouzon syndrome, megalocornea-mental retardation syndrome etc. Eyes are usually highly ...
For example, the patients with mucolipidosis syndrome inherit a mutation caused by insertion of a 93bp fragment of ...
GeneReviews/NCBI/NIH/UW entry on Mucolipidosis III Alpha/Beta GeneReviews/NIH/NCBI/UW entry on Mucolipidosis II GeneReviews/NIH ... It is associated with the following conditions: mucolipidosis II alpha/beta (I-cell disease) - GNPTAB mucolipidosis III alpha/ ... Online Mendelian Inheritance in Man (OMIM): MUCOLIPIDOSIS II ALPHA/BETA - 252500 Online Mendelian Inheritance in Man (OMIM): ... MUCOLIPIDOSIS III GAMMA - 252605 Hoek KS, Schlegel NC, Eichhoff OM, et al. (2008). "Novel MITF targets identified using a two- ...
Mucha-Habermann disease Muckle-Wells syndrome Mucoepithelial dysplasia Mucolipidosis type 1 Mucolipidosis type 3 Mucolipidosis ...
... and mucolipidosis IV among certain Jewish communities, is another screening program which has drawn comparisons with liberal ...
Medical genetics of Ashkenazi Jews mucolipidoses at NINDS RESERVED, INSERM US14 -- ALL RIGHTS. "Orphanet: Mucolipidosis type II ... The mucolipidoses are inherited in an autosomal recessive manner, that is, they occur only when a child inherits two copies of ... Mucolipidosis is a group of inherited metabolic disorders that affect the bodys ability to carry out the normal turnover of ... Mucolipidosis types II and III (ML II and ML III) result from a deficiency of the enzyme N-acetylglucosamine-1- ...
Mucolipidosis III alpha/beta is a disorder that affects many parts of the body. Explore symptoms, inheritance, genetics of this ... Mucolipidosis III alpha/beta and mucolipidosis II alpha/beta represent two ends of a spectrum of disease severity. ... Mucolipidosis II (I-cell disease) and mucolipidosis IIIA (classical pseudo-hurler polydystrophy) are caused by mutations in the ... When Mucolipidosis III meets Mucolipidosis II: GNPTA gene mutations in 24 patients. Mol Genet Metab. 2006 Aug;88(4):359-63. doi ...
Please note that NORD provides this information for the benefit of the rare disease community. NORD is not a medical provider or health care facility and thus can neither diagnose any disease or disorder nor endorse or recommend any specific medical treatments. Patients must rely on the personal and individualized medical advice of their qualified health care professionals before seeking any information related to their particular diagnosis, cure or treatment of a condition or disorder.. ...
Mucolipidosis I (ML I), or sialidosis, is a rare, inherited disorder in which genetic variations disrupt the normal activity of ... Mucolipidosis I , Symptoms & Causes. What are the symptoms of Mucolipidosis I?. Symptoms of Mucolipidosis I fall on a broad ... What is Mucolipidosis I (ML I)?. Mucolipidosis I (ML I) is a rare, inherited disorder. Mucolipidosis I is also known as ... Mucolipidosis I , Diagnosis & Treatments. How do we treat Mucolipidosis I?. There are currently no approved therapies which ...
Mucolipidosis type II a/ß with a homozygous missense mutation in the GNPTAB gene. Am J Med Genet A. 2012 Apr 11. [QxMD MEDLINE ... The genetic mucolipidoses. Diagnosis and differential diagnosis. Humangenetik. 1970. 9(2):113-39. [QxMD MEDLINE Link]. ... Mucolipidosis II-related mutations inhibit the exit from the endoplasmic reticulum and proteolytic cleavage of GlcNAc-1- ... Otomo T, Higaki K, Nanba E, Ozono K, Sakai N. Lysosomal storage causes cellular dysfunction in mucolipidosis II skin ...
Mucolipidosis type I (ML I) is a rare inherited lysosomal storage disease that has clinical and histologic findings similar to ... encoded search term (Sialidosis (Mucolipidosis I)) and Sialidosis (Mucolipidosis I) What to Read Next on Medscape ... Sialidosis (Mucolipidosis I). Updated: Oct 08, 2019 * Author: Karl S Roth, MD; Chief Editor: Luis O Rohena, MD, PhD, FAAP, ... Mucolipidosis I (acid neuraminidase deficiency). Three cases and delineation of the variability of the phenotype. Am J Dis ...
Mucolipidosis II (I cell Disorder) Market was USD 12.80 billion in 2022, and will reach USD 15.80 billion by 2030, growing at a ... Mucolipidosis II (I cell Disorder) Market Analysis and Size. I-cell disease (mucolipidosis II) (I cell disorder) refers to a ... Global Mucolipidosis II (I cell Disorder) Market Scope. The global mucolipidosis II (I cell disorder) market is segmented on ... Mucolipidosis II (I cell Disorder) market Regional Analysis/Insights. The global mucolipidosis II (I cell disorder) market is ...
Mucolipidosis type IV (ML IV) also known as ganglioside sialidase deficiency and sialolipidosis, is an inherited lysosomal ... Mucolipidosis type IV (ML IV) also known as ganglioside sialidase deficiency and sialolipidosis, is an inherited lysosomal ...
... external resources ICD-10 E75.1 OMIM 252650 DiseasesDB 32693 MeSH C05.116.198.371 Mucolipidosis ... Mucolipidosis type IV (ML IV), like other types of mucolipidosis is an inherited neurodegenerative lysosomal storage disorder. ... See the equivalent section in the main mucolipidosis article. Epidemiology. Ashkenazi Jews have a high carrier frequency of 1: ... This type of mucolipidosis is caused by mutation of a non-selective cation channel, TRPML1. These mutations disrupt lysosomal ...
Mucolipidosis type I (ML I) is a rare inherited lysosomal storage disease that has clinical and histologic findings similar to ... encoded search term (Sialidosis (Mucolipidosis I)) and Sialidosis (Mucolipidosis I) What to Read Next on Medscape ... Sialidosis (Mucolipidosis I) Medication. Updated: Dec 13, 2013 * Author: Karl S Roth, MD; Chief Editor: Luis O Rohena, MD more ... Mucolipidosis I (acid neuraminidase deficiency). Three cases and delineation of the variability of the phenotype. Am J Dis ...
Use tab to navigate through the menu items ...
Mucolipidosis I), Mucolipidosis II, II/III, III alpha/beta, Mucolipidosis III Gamma, and Schindler Disease. ... Mucolipidosis I), Mucolipidosis II, II/III, III alpha/beta, Mucolipidosis III Gamma, and Schindler Disease. ... Mucolipidosis type II. Synonyms: I-cell disease , Mucolipidosis type II alpha/beta , N-acetylglucosamine 1-phosphotransferase ... Cure Mucolipidosis. Cure Mucolipidosis is a global organization that is committed to the identification and treatment of ...
Mucolipidosis type I (ML I) is a rare inherited lysosomal storage disease that has clinical and histologic findings similar to ... encoded search term (Sialidosis (Mucolipidosis I)) and Sialidosis (Mucolipidosis I) What to Read Next on Medscape ... Mucolipidosis type I (ML I) is a rare inherited lysosomal storage disease that has clinical and histologic findings similar to ... Mucolipidosis I (acid neuraminidase deficiency). Three cases and delineation of the variability of the phenotype. Am J Dis ...
Cherry red spot in sialidosis (mucolipidosis type I). Heroman JW, Rychwalski P, Barr CC. Cherry red spot in sialidosis ( ...
Impaired myelination and reduced brain ferric iron in the mouse model of mucolipidosis IV Yulia Grishchuk, Yulia Grishchuk ‡ ... Mucolipidosis type IV (MLIV) is a lysosomal storage disease caused by mutations in the MCOLN1 gene, which encodes the lysosomal ... Mucolipidosis type IV (MLIV) is a lysosomal storage disease caused by mutations in MCOLN1, which encodes the lysosomal ion ... Mucolipidosis type IV is caused by mutations in a gene encoding a novel transient receptor potential channel ...
Mucopolysaccharidosis, Glycoproteinosis, and Mucolipidosis." Rudolphs Pediatrics, 22e Rudolph CD, Rudolph AM, Lister GE, First ... Mucopolysaccharidosis, Glycoproteinosis, and Mucolipidosis. In: Rudolph CD, Rudolph AM, Lister GE, First LR, Gershon AA. ... mucopolysaccharidosis, glycoproteinosis, and mucolipidosis. Rudolph CD, Rudolph AM, Lister GE, First LR, Gershon AA. Rudolph C. ...
Mucolipidoses see Metabolic Disorders * Mucopolysaccharidoses see Carbohydrate Metabolism Disorders * Niemann-Pick Disease see ...
Mucolipidosis Type IV and our test Mucolipidosis IV is a rare genetic disorder characterized by developmental delay and gradual ... Mucolipidosis Type IV Neuronal Ceroid Lipofuscinosis (CLN5-Related) Neuronal Ceroid Lipofuscinosis (PPT1-Related) Niemann-Pick ... Carrier testing for mucolipidosis IV is recommended by the American College of Medical Genetics (ACMG) for people of Ashkenazi ...
Carpal tunnel syndrome (CTS) is the most common focal peripheral neuropathy. CTS is caused by entrapment of the median nerve at the wrist as it traverses through the carpal tunnel.
Macular cherry-red spot and corneal haze in sialidosis (mucolipidosis type 1) [1]. / Goldberg, Morton F. In: Archives of ... Goldberg, Morton F. / Macular cherry-red spot and corneal haze in sialidosis (mucolipidosis type 1) [1]. In: Archives of ... Goldberg, M. F. (2008). Macular cherry-red spot and corneal haze in sialidosis (mucolipidosis type 1) [1]. Archives of ... Goldberg, MF 2008, Macular cherry-red spot and corneal haze in sialidosis (mucolipidosis type 1) [1], Archives of ...
Mucolipidosis II (ML II), also known as I-Cell disease, and Mucolipidosis IIIA (ML IIIA), also known as Pseudo-Hurler ...
Sialidosis (Mucolipidosis I) * Genetics of Glycogen-Storage Disease Type II (Pompe Disease) ...
Mucolipidosis type IV (MLIV) is an autosomal recessive lysosomal storage disorder caused by mutations in the MCOLN1 gene coding ... Mucolipidosis type IV (MLIV) is an autosomal recessive lysosomal storage disorder caused by mutations in the MCOLN1 gene coding ... Cell Line, Tumor, Hela Cells, Animals, Zebrafish, Humans, Mucolipidoses, Disease Models, Animal, Zebrafish Proteins, Sequence ... the putative zebrafish co-orthologs of the gene responsible for human mucolipidosis type IV. ...
Neurologic abnormalities in mouse models of the lysosomal storage disorders mucolipidosis II and mucolipidosis III γ. PloS one ... Neurologic abnormalities in mouse models of the lysosomal storage disorders mucolipidosis II and mucolipidosis III γ. In: PloS ... Neurologic abnormalities in mouse models of the lysosomal storage disorders mucolipidosis II and mucolipidosis III γ. / Idol, ... title = "Neurologic abnormalities in mouse models of the lysosomal storage disorders mucolipidosis II and mucolipidosis III γ", ...
Lysosomal dysfunction causes neurodegeneration in mucolipidosis II knock-in mice. Brain 2012; 135: 2661-2675. ... a study on type-II mucolipidosis, a neurometabolic lysosomal trafficking disorder of childhood, revealed accumulation of ...
ICD-10 code E75.24 for Niemann-Pick disease is a medical classification as listed by WHO under the range -Metabolic disorders .
Mucolipidosis IV (MLIV) is an orphan neurodevelopmental disease that causes severe neurologic dysfunction and loss of vision ... Fingolimod Phosphate Inhibits Astrocyte Inflammatory Activity in Mucolipidosis IV. Weinstock L, Furness AM, Herron S, Smith SS ... Fingolimod Phosphate Inhibits Astrocyte Inflammatory Activity in Mucolipidosis IV. Weinstock L, Furness AM, Herron S, Smith SS ...
Mucolipidosis type IV: MedlinePlus Genetics (National Library of Medicine) * Mucopolysaccharidosis type I: MedlinePlus Genetics ...
  • However, type I (sialidosis) is now classified as a glycoproteinosis, and type IV (Mucolipidosis type IV) is now classified as a gangliosidosis. (wikipedia.org)
  • Mucolipidosis I is also known as sialidosis. (childrenshospital.org)
  • Sialidosis, also known as mucolipidosis type I (ML I), is a rare inherited lysosomal storage disease that has clinical and histologic findings similar to the mucopolysaccharidoses and the sphingolipidoses. (medscape.com)
  • Sphranger J, Gehler J, Cantz M. Mucolipidosis I--a sialidosis. (medscape.com)
  • Heroman JW, Rychwalski P, Barr CC. Cherry red spot in sialidosis (mucolipidosis type I) . Arch Ophthalmol. (arizona.edu)
  • Goldberg, MF 2008, ' Macular cherry-red spot and corneal haze in sialidosis (mucolipidosis type 1) [1] ', Archives of ophthalmology , vol. 126, no. 12. (johnshopkins.edu)
  • Cure Mucolipidosis is a global organization that is committed to the identification and treatment of Mucolipidosis through education, advocacy and research. (globalgenes.org)
  • Cure Mucolipidosis will form partnerships with Science, Medicine and industry and will work towards finding a cure for people affected by Mucolipidosis globally. (globalgenes.org)
  • Medical genetics of Ashkenazi Jews mucolipidoses at NINDS RESERVED, INSERM US14 -- ALL RIGHTS. (wikipedia.org)
  • Conditions that cause molecules to build up inside lysosomes, including mucolipidosis III alpha/beta, are called lysosomal storage disorders. (medlineplus.gov)
  • The signs and symptoms of mucolipidosis III alpha/beta are most likely due to the shortage of digestive enzymes inside lysosomes and the effects these enzymes have outside the cell. (medlineplus.gov)
  • Mucolipidosis I is caused by a mutation on the NEU1 gene, resulting in a deficiency in an enzyme known as neuraminidase 1, which lysosomes require to properly break down large sugar molecules inside the body's cells. (childrenshospital.org)
  • In individuals with mucolipidosis II, lysosomes do not perform their normal role effectively, leading to the accumulation of certain substances within the cell. (databridgemarketresearch.com)
  • The mucolipidoses are inherited in an autosomal recessive manner, that is, they occur only when a child inherits two copies of the defective gene, one from each parent. (wikipedia.org)
  • Mucolipidosis type IV (MLIV) is an autosomal recessive lysosomal storage disorder caused by mutations in the MCOLN1 gene coding for mucolipin-1 (TRPML1). (ox.ac.uk)
  • The Ashkenazi Jewish Panel includes the following diseases: Bloom syndrome, Canavan disease, Fanconi anemia type C, familial dysautonomia, Gaucher disease, glycogen storage disease type 1a, Mucolipidosis IV, Neimann-Pick disease, and Tay-Sachs disease. (cdc.gov)
  • Mucolipidosis II (ML II), also known as I-Cell disease, and Mucolipidosis IIIA (ML IIIA), also known as Pseudo-Hurler Polydystrophy, are lysosomal storage disorders caused by a deficiency of N-acetylglucosamine-1-phosphotransferase (NAPT). (ggc.org)
  • a deficiency or defect in this enzyme results in two forms of mucolipidoses, I-cell disease, and pseudo-Hurler polydystrophy. (theodora.com)
  • Mucolipidosis III alpha/beta and mucolipidosis II alpha/beta represent two ends of a spectrum of disease severity. (medlineplus.gov)
  • Children who show signs and symptoms of Mucolipidosis I at birth typically have a more severe form of the disease. (childrenshospital.org)
  • Spranger and Wiedermann subsequently classified this disease as mucolipidosis type II (ML II) because it had clinical characteristics that included mucopolysaccharidoses and sphingolipidoses. (medscape.com)
  • Initially classified as a lipomucopolysaccharidosis, this disease was later classified into the group of similar diseases now known as the mucolipidoses. (medscape.com)
  • I-cell disease (mucolipidosis II) (I cell disorder) refers to a rare inherited metabolic disorder that is generally characterized by coarse facial features such as mental retardation and skeletal abnormalities. (databridgemarketresearch.com)
  • The increase in the incidences of I-cell disease (mucolipidosis II) (I cell Disorder) among population across the globe acts as one of the major factors driving the growth of global mucolipidosis II (I cell disorder) market. (databridgemarketresearch.com)
  • Mucolipidosis II, also known as I-cell disease, is a rare inherited genetic disorder that falls under the broader category of lysosomal storage diseases. (databridgemarketresearch.com)
  • Mucolipidosis type IV (ML IV) also known as ganglioside sialidase deficiency and sialolipidosis, is an inherited lysosomal storage disease, belonging to the group of oligosaccharidosis that affects many organs and tissues, including the nervous system. (mpssociety.org.uk)
  • 3) Inherited pathogenic alleles of LYSET can cause a severe inherited disease which resembles GlcNAc-1-phosphotransferase deficiency (i.e., mucolipidosis type II). (stanford.edu)
  • Mucolipidosis II/I-Cell disease) - Alzheimer disease - Hermansky Pudlak Syndrome (pigmentation bleeding disorder) - Cancer - virus and bacterial infections - ARC syndrome -Microvillar inclusion Disease. (umcutrecht.nl)
  • Mucolipidosis III alpha/beta is a disorder that affects many parts of the body. (medlineplus.gov)
  • Mucolipidosis III alpha/beta is a rare disorder, although its exact prevalence is unknown. (medlineplus.gov)
  • Mutations in the GNPTAB gene can also cause a similar but more severe disorder called mucolipidosis II alpha/beta . (medlineplus.gov)
  • Mucolipidosis I (ML I) is a rare, inherited disorder. (childrenshospital.org)
  • Data Bridge Market Research analyses that the global mucolipidosis II (I cell disorder) market which was USD 12.80 billion in 2022, is expected to reach USD 15.80 billion by 2030, and is expected to undergo a CAGR of 3.9% during the forecast period 2023-2030. (databridgemarketresearch.com)
  • Abnormal Curvature of the Spine" dominates the symptoms segment of the global mucolipidosis II (I cell disorder) market owing to the rising incidences of genetic diseases and other related issues. (databridgemarketresearch.com)
  • Mucolipidosis type IV ( ML IV ), like other types of mucolipidosis is an inherited neurodegenerative lysosomal storage disorder. (chemeurope.com)
  • Mutations in the α/β subunit precursor gene cause the severe lysosomal storage disorder mucolipidosis II (ML II) or the more moderate mucolipidosis III alpha/beta (ML III α/β), while mutations in the γ subunit gene cause the mildest disorder, mucolipidosis III gamma (ML III γ). (wustl.edu)
  • GlcNAc-1-phosphotransferase deficiency leads to the severe lysosomal storage disorder mucolipidosis II (MLII). (stanford.edu)
  • Their son Christopher was born with Mucolipidosis II, a very rare, terminal genetic disorder which caused both physical and developmental disabilities. (ncpd.org)
  • Mucolipidosis IV (MLIV) is caused by mutations in the gene MCOLN1. (escholarship.org)
  • When originally named, the mucolipidoses derived their name from the similarity in presentation to both mucopolysaccharidoses and sphingolipidoses. (wikipedia.org)
  • Mucolipidosis is a group of inherited metabolic disorders that affect the body's ability to carry out the normal turnover of various materials within cells. (wikipedia.org)
  • Myelination deficits and severely dysmorphic corpus callosum were present early and resembled white matter pathology in mucolipidosis IV patients. (escholarship.org)
  • Mutations in the GNPTAB gene cause mucolipidosis III alpha/beta. (medlineplus.gov)
  • Mutations in the GNPTAB gene that cause mucolipidosis III alpha/beta result in reduced activity of GlcNAc-1-phosphotransferase. (medlineplus.gov)
  • These results indicate the early involvement of glia, and challenge the traditional view of mucolipidosis IV as an overtly neurodegenerative condition. (escholarship.org)
  • People with mucolipidosis III alpha/beta often have heart valve abnormalities and mild clouding of the clear covering of the eye ( cornea ). (medlineplus.gov)
  • A rare severe form of mucolipidosis characterized by growth retardation skeletal abnormalities (dysostosis multiplex craniosynostosis contractures of the joints and osteopenia) facial dysmorphism stiff skin obstructive airway cardiomegaly and severe global developmental delay. (globalgenes.org)
  • Spranger JW, Wiedemann HR. The genetic mucolipidoses. (medscape.com)
  • Mucolipidosis types II and III (ML II and ML III) result from a deficiency of the enzyme N-acetylglucosamine-1-phosphotransferase, which phosphorylates target carbohydrate residues on N-linked glycoproteins. (wikipedia.org)
  • Mucolipidosis I (acid neuraminidase deficiency). (medscape.com)
  • This type of mucolipidosis is caused by mutation of a non-selective cation channel, TRPML1 . (chemeurope.com)
  • There are currently no approved therapies which reverse the effects of Mucolipidosis I. Current approaches involve managing specific symptoms through targeted therapies and collaboration between specialists. (childrenshospital.org)
  • To promote and support a global multi-stakeholder collaboration for Mucolipidosis. (globalgenes.org)
  • Early evidence of delayed oligodendrocyte maturation in the mouse model of mucolipidosis type IV. (harvard.edu)
  • Using an accurate mouse model of mucolipidosis IV, we observed early behavioral deficits which were accompanied by activation of microglia and astrocytes. (escholarship.org)
  • Characterization and expression analysis of mcoln1.1 and mcoln1.2, the putative zebrafish co-orthologs of the gene responsible for human mucolipidosis type IV. (ox.ac.uk)
  • Poor mental capacities, and difficulty reaching physical developmental milestones may also be result of mucolipidosis. (wikipedia.org)
  • Osteoporosis and progressive joint problems also cause bone pain that becomes more severe over time in people with mucolipidosis III alpha/beta. (medlineplus.gov)
  • See the equivalent section in the main mucolipidosis article . (chemeurope.com)
  • Individuals with mucolipidosis III alpha/beta grow slowly and have short stature. (medlineplus.gov)
  • Individuals with mucolipidosis III alpha/beta generally survive into adulthood, but they may have a shortened lifespan. (medlineplus.gov)
  • Our Vision To serve as a resource for stakeholders in the work, identification, treatment, and continual developments towards a cure for Mucolipidosis. (globalgenes.org)
  • We work with the broad array of world-class specialists at Boston Children's to optimize the care we provide your child with Mucolipidosis I. (childrenshospital.org)